

MP75-17 - Ethnic Variation in Prostate Cancer Detection: A Hypothesis Generating Study for use of the Stockholm3 Test in an American Cohort



Hari T. Vigneswaran^{1,3}, Andrea Discacciati¹, Peter H. Gann, MD², Henrik Grönberg, MD¹, Martin Eklund¹, Michael R. Abern³

¹Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, ²University of Illinois at Chicago, Department of Pathology, ³University of Illinois at Chicago, Department of Urology



BACKGROUND

- African American men have been shown to have higher PSA, more likely to have prostate cancer (PC), and more likely to have high grade of cancer at PC diagnosis compared to Caucasian men
- Stockholm3 is a validated model used for PC detection, incorporating: PC-associated protein levels + a germline genetic risk score + prebiopsy clinical information
- It is unknown if Stockholm3 would be useful in an American cohort where clinical practice patterns and ethnicity differ

OBJECTIVES

- To evaluate if the detection of ISUP grade group ≥ 2 (GG ≥ 2 PC) between Chicago and Stockholm once risk profiles are equivalent
- To perform secondary analysis with Stockholm3 in matched Stockholm men to ethnicity-specific risk profiles from Chicago

METHODS

Design: Retrospective analysis

Setting: Men who underwent prostate biopsies; Age: 50-69 years

Population: STHLM3 cohort from May 2012 to May 2013 (n = 7,417) & Uni of IL Chicago from June 2016 to July 2019 (n = 634)

Outcome: Detection of GG ≥ 2 PC on biopsy

Race/ethnicity: African Am (AA), Caucasian, and Hispanic

METHODS

Propensity scores (PS) were estimated for each man in the study using pre-biopsy covariates including:

- Age
 - PSA
 - Prostate volume
 - Family history of PC
 - Prior negative biopsy
 - Use of a 5-alpha reductase inhibitor
- Swedish men were matched to ethnic groups risk profiles from Chicago
 - Area under the receiver operating curve (AUC) for Stockholm3 and PSA was assessed in matched cohorts

RESULTS

	Chicago			Stockholm	
	African American	Caucasian	Hispanic	Overall	STHLM3
	n = 303 (60 %)	n = 62 (12%)	n = 106 (21%)	N = 504	N = 6980
Age (years)*	61.0 [56.0, 65.0]	61.0 [58.0, 65.0]	62.0 [58.0, 65.0]	61.0 [57.0, 65.0]	64.0 [59.0, 67.0]
PSA (ng/mL)*	7.50 [5.30, 11.7]	5.00 [4.40, 6.98]	6.45 [5.05, 10.6]	6.60 [5.08, 10.7]	3.70 [3.00, 5.20]
Prostate volume (cc)*	34.0 [24.4, 53.5]	36.5 [27.0, 47.8]	41.2 [31.4, 64.2]	36.0 [26.0, 55.0]	40.0 [30.0, 54.0]
Family Hx of PCa % (n)	23.4% (71/303)	25.8% (16/62)	19.8% (21/106)	22.0% (111/504)	15.1% (1057/6980)
5- α Reductase Inhib. % (n)	3.0% (9/303)	3.2% (2/62)	8.5% (9/106)	4.4% (22/504)	2.3% (164/6980)
Prior Negative Biopsy % (n)	5.9% (18/303)	8.1% (5/62)	15.1% (16/106)	7.9% (39/504)	6.0% (419/6980)




Figure 1: Density plots of covariates prior to propensity score matching for African American men and STHLM3 men

RESULTS




Figure 2: Density plots of covariates after propensity score matching for African American men and STHLM3 men

	Before Propensity Score Matching				After Propensity Score Matching				SMD
	STHLM3	Chicago AA	STHLM3*	Chicago AA*	STHLM3	Chicago AA	STHLM3*	Chicago AA*	
Age (years)	Mean 62.8 SD 5.2	Mean 60.5 SD 5.5	SMD -0.422	Mean 59.8 SD 5.3	Mean 60.5 SD 5.4	SMD 0.125			
PSA (ng/mL)	Mean 5.0 SD 8.5	Mean 27.0 SD 115.8	SMD 0.190	Mean 12.9 SD 21.1	Mean 12.4 SD 17.2	SMD -0.004			
Prostate Volume (cc)	Mean 44.7 SD 21.4	Mean 42.5 SD 27.1	SMD -0.082	Mean 39.9 SD 20.3	Mean 43.0 SD 27.3	SMD 0.115			
Family History of PCa (%)	Mean 15.1 SD 23.4	Mean 23.4 SD 0.083	SMD 0.083	Mean 24.5 SD 23.9	Mean 23.9 SD -0.006	SMD -0.006			
5-alpha Reductase Use (%)	Mean 2.3 SD 3.0	Mean 3.0 SD 0.006	SMD 0.006	Mean 3.5 SD 3.1	Mean 3.1 SD -0.005	SMD -0.005			
Previous Negative Biopsy (%)	Mean 6.0 SD 5.9	Mean -0.001 SD 8.0	SMD -0.001	Mean 6.1 SD 6.1	Mean -0.018 SD -0.018	SMD -0.018			

Table 2 : Before and after matching between African American and Stockholm subjects




Figure 3: GG ≥ 2 PC detection rates seen in men from different ethnicity groups and risk-matched Swedish men

Detection of GG ≥ 2 PC was far higher in AA Chicago men even after matching: 51% versus 34% (OR: 2.1, 95% CI: 1.57–2.74, $P < 0.001$) compared to matched Caucasian and Hispanic cohorts

RESULTS




Figure 4: Receiver operating characteristics for GG ≥ 2 PC detection with PSA and Stockholm3 in Swedish men with risk profiles matched to different ethnicity groups
AA (African American), NHC (non-Hispanic Caucasian), HC (Hispanic Caucasian, CHI (Chicago), STHLM (Stockholm)

DISCUSSION

- Genome-wide association studies have shown overlap of risk variants previously identified in European men with African American men
- A prostate risk model using a germline genetic risk has not been assessed in a multiethnic population

CONCLUSION

- There may be additional factors associated with increased detection of PC in African American men even after adjusting for known PC risk factors
- Further studies are needed and underway to assess biologic risk in multiethnic populations